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Abstract
Background: Traditional antibiotics are increasingly suffering from the emergence of multidrug resistance amongst
pathogenic bacteria leading to a range of novel approaches to control microbial infections being investigated as potential
alternative treatments. One plausible antimicrobial alternative could be the combination of conventional antimicrobial
agents/antibiotics with small molecules which block multidrug efflux systems known as efflux pump inhibitors. Bioassay-
driven purification and structural determination of compounds from plant sources have yielded a number of pump
inhibitors which acted against gram positive bacteria.
Methodology/Principal Findings: In this study we report the identification and characterization of 49,59-O-dicaffeoylquinic
acid (49,59-ODCQA) from Artemisia absinthium as a pump inhibitor with a potential of targeting efflux systems in a wide
panel of Gram-positive human pathogenic bacteria. Separation and identification of phenolic compounds (chlorogenic acid,
39,59-ODCQA, 49,59-ODCQA) was based on hyphenated chromatographic techniques such as liquid chromatography with
post column solid-phase extraction coupled with nuclear magnetic resonance spectroscopy and mass spectroscopy.
Microbial susceptibility testing and potentiation of well know pump substrates revealed at least two active compounds;
chlorogenic acid with weak antimicrobial activity and 49,59-ODCQA with pump inhibitory activity whereas 39,59-ODCQA was
ineffective. These intitial findings were further validated with checkerboard, berberine accumulation efflux assays using
efflux-related phenotypes and clinical isolates as well as molecular modeling methodology.
Conclusions/Significance: These techniques facilitated the direct analysis of the active components from plant extracts, as
well as dramatically reduced the time needed to analyze the compounds, without the need for prior isolation. The
calculated energetics of the docking poses supported the biological information for the inhibitory capabilities of 49,59-
ODCQA and furthermore contributed evidence that CQAs show a preferential binding to Major Facilitator Super family
efflux systems, a key multidrug resistance determinant in gram-positive bacteria.
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Introduction
Multi-drug resistant microbial infections caused by Gram-
positive bacteria such as Staphylococcus aureus and Enterococcus faecalis
represent an exponentially growing problem affecting communi-
ties worldwide. Efflux mechanisms have become broadly recog-
nized as major components of resistance to many classes of
antibiotics [1,2]. Some efflux pumps selectively extrude specific
antibiotics while others, referred to as multidrug efflux pumps
(MEPs), expel a variety of structurally and functionally diverse
compounds [3] in addition to a variety of other physiological roles
[4]. A novel and promising approach to deal with multidrug
resistance is to improve the clinical performance of various
antibiotics by employing efflux pump inhibitors (EPIs) [5,6]. Plants
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have been explored comprehensively as potential sources of
antimicrobials [7,8]. It has been established that disabling MEPs in
Gram-negative species using a combination of MEP mutants and
synthetic EPIs leads to a striking increase in the activity of
numerous plant compounds [9]. Several Berberis medicinal plants
(Berberis repens, B. aquifolia, and B. fremontii) that produce the plant
antimicrobial berberine also synthesized an inhibitor of the
Staphylococcus aureus NorA MEP identified as 59-methoxyhydno-
carpin (59-MHC) [10]. Identification of 59-MHC intensified the
search for natural EPIs of plant origin. Bioassay driven purification
and structural determination of compounds from various plant
sources yielded a number of EPIs acting against Gram- positive
bacteria with activities similar to 59-MHC [11,12,13,14,15,16].
Gram-negative bacteria and fungi comprise the main groups of
plant pathogens, and it is important to determine whether the
antimicrobial/EPI synergy is a general mechanism of plant
defense.
Artemisia is a fairly large genus within the family of the Asteraceae
(Compositae), with more than 200 individual species [17]. Artemisia
absinthium, best known as the principal ingredient in the infamous
Absinthe drink, has been used medicinally since the times of
ancient Greece, and also in western European systems of
traditional medicine [17]. It was recently reported that the
essential oils occurring in flowers and aerial parts from A.
absinthium have antimicrobial properties [17]. Moreover aqueous
extracts of A. absinthium are rich in caffeoyl and dicaffeoylquinic
acids, which are known to inhibit HIV-1 integrase from
integrating the reversibly transcribed viral DNA into host cell
DNA [18]. Furthermore, these components are hepatoprotective,
anti-histaminic, hypocholesterolemic, anti-spasmodic, and poten-
tially antimicrobial. They also demonstrate high antioxidant
activity [19] due to their o-quinone moieties. Caffeoylquinic acids
could inhibit oxidative damage to both low-density lipoprotein
[20] and linolenic acid [21] by scavenging reactive oxygen species
(ROS) related to cancer and cardiovascular diseases. It has been
reported that chlorogenic acid (5-O-caffeoylquinic acid) had
inhibitory effects on carcinogenesis in the large intestine, liver,
and tongue, and exhibited protective effects on oxidative stress in
vivo [22].
The effort to discover plant EPIs, a process ranging from
identifying a hit to isolating a pure compound, presents a distinct
bottleneck: the lack of comprehensive, chemically and biologically
representative natural product extract libraries. Analysis of natural
product extracts is time-consuming and laborious, consisting of the
isolation of different components of the extract and the successive
identification of these compounds by spectrometric data acquisi-
tion. We have identified EPI activity against Gram-positive
bacteria in A. absinthium extracts. We dramatically expedited the
analysis of A. absinthium aquatic infusions using analytical
techniques (LC-SPE-NMR and LC-MS), revealing caffeoylquinic
acids as key components. Subsequent antimicrobial susceptibility
testing of berberine uptake and a competitive efflux assay
employing the pure compounds was conducted. An array of
pathogens, including knock out and over expression MEP
mutants, strongly supported the hypothesis that 49,59-ODCQA
behaves as a designated EPI for the major facilitator super family
(MFS) MEPs of the Gram-positive bacteria: S. aureus, and
Enterococcus faecalis.
Results and Discussion
Antimicrobial and EPI activity of extracts
The experimental approach to detect EPI activity was to test the
combined action of a plant extract (the no alkaloid fraction) with
berberine added at a sub inhibitory concentration. Extracts that
inhibited cell growth in the presence of berberine and had no
activity when added alone were likely to contain an EPI.
Chloroform extracts of leaves from A. absinthum had no
antimicrobial activity alone at up to 500 mg/ml (Table 1), but
inhibited Staphylococcus aureus, Enterococcus faecalis and Bacillus cereus
growth completely in the presence of 30 mg/ml berberine (15 mg/
ml berberine for Bacillus cells), a concentration one-eighth the
MIC for this substance (data not shown).
The three main components of the extract consisting 40% of the
total mass were identified via LC-UV-SPE-NMR [23] and LC-
MS. The molecular ion in the ESI negative mode of the first peak
was m/z = 353 and the MS2 gave a characteristic chlorogenic acid
fragmentation pattern [24]. The structure was confirmed by the
respective 1H-NMR analysis. The second and third main
components of the extract were co-eluted from the chromato-
graphic column. By the spectral data obtained it was concluded
that two dicaffeoylquinic acid isomers were present (39,59-ODCQA
and 49,59-ODCQA) (Figures S1, S2).
Antimicrobial and EPI activity of CQAs
The A. absinthum extract was tested against a panel of human
and plant pathogenic bacteria both for direct antimicrobial and
EPI activity. The extract exhibited neither antimicrobial activity
Table 1. Antimicrobial susceptibility for A. absinthum and acquired CQA derivatives.
MIC (mg ml21)
Strain Extr 39,59-ODCQA 49,59-ODCQA 59-OCQA 19,39-ODCQA 19,59-ODCQA
S. aureus 8325-4 256 .128 .128 128 .128 .128
norA 256 .128 .128 64 .128 .128
NorA++ 256 .128 .128 .128 .128 .128
CA-MRSA 256 .128 .128 .128 .128 .128
B. cereus 128 .128 .128 64 .128 .128
E. faecalis 256 .128 .128 64 .128 .128
norA 256 256 .256 32 .256 .256
E. coli .256 .256 .256 .256 .256 .256
C. albicans .256 .256 .256 .256 .256 .256
All MIC determinations were performed in triplicate.
doi:10.1371/journal.pone.0018127.t001
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nor EPI activity in Escherichia coli or Candida albicans (concentration
range 150–500 mg/mL). It showed no apparent direct antimicro-
bial activity (MICs in the range of 128–256 mg/mL for all Gram-
positive bacteria tested), but completely inhibited growth in
concentrations lower than 50 mg/mL when berberine was added
in sub inhibitory concentrations (30 mg/mL for S. aureus and E.
faecalis, and 15 mg/mL for B. cereus).
We obtained 59-O-caffeoylquinic (59-OCQA) acid and perace-
tylderivatives 19,39- and 19,59-ODCQA, 39,59-ODCQA and 49,59-
ODCQA, and tested their direct antimicrobial and EPI activity
(Table 1). 59-OCQA was the only molecule with weak direct
antimicrobial activity against the Gram-positive bacteria (B. cereus
and E. faecalis, MIC 64 mg/ml). There was a 4-fold difference
between MICs in S. aureus 8325-4 and the isogenic NorA mutant
providing supporting evidence for 59-OCQA as a potential
substrate of MFS efflux systems. All other derivatives were
virtually inactive with significantly higher MICs (.128 mg/ml)
against all microorganisms in the panel tested.
Toxicity studies
Hemolysis experiments using sheep erythrocytes and DCQA
derivatives demonstrated no hemolytic activity at 50 mM, a
concentration higher than the MICs for Gram-positive and
significantly higher than the concentration used for antimicrobial
potentiation (Figure 1). There are a few brief reports discussing
the toxic effect of 59-OCQA on human oral squamous cell
carcinoma (HSC-2) and salivary gland tumor (HSG) cell lines, as
compared with that against human gingival fibroblast (HGF), and
erythrocytes in a mM range [25]. The toxic effect is attributed to
the potential of the compound to generate reactive oxygen species
(ROS). A dose-response experiment using erythrocytes was also
able to detect toxicity of 59-OCQA at fairly low concentrations, (1-
5 mM) whereas 39,59- and 49,59-ODCQAs did not exhibit any cell-
lytic properties at significantly higher concentrations (50 mM). This
trend, together with existing studies [22,26], suggest that 59-
OCQA is toxic at high concentrations, and implies that the other
derivatives appear to have a different interaction pattern with
mammalian cells, suggesting that a therapeutic window may exist
in both cases. 39,59-ODCQA and 49,59-ODCQA showed extreme-
ly low toxicity to the blood cells indicating that the antimicrobial
activity and toxicity patterns are relatively similar related to the
differences in substitution moieties.
Potentiation of antibiotics by 49,59-ODCQA
We conducted a checkerboard assay using berberine and CQAs
against S. aureus 8325-4 (Table 2). This method supports evidence
for synergy, competition or antagonism for selected compounds as
it is reflected by the FIC index (FICI). A FICI of #0.5 indicates
synergistic interaction. FICI is calculated as the sum of the FICs of
each agent. The FIC of each agent is calculated as the MIC of the
agent in combination divided by the MIC of the agent. This
indicated a synergistic effect for 49,59-ODCQA, an9d competition
for the other two derivatives. We employ a clinical MRSA strain
(CA-300) and conducted extensive checkerboard assays using an
array of known MFS substrates and 49,59-ODCQA suggesting a
promising range of activity both in different strains and clinically
relevant compounds (Table 3). We further evaluated the ability of
49,59-ODCQA to potentiate designated substrates of MFS and
known antibiotics against a panel of Gram-positive phenotypes
(Tables 4, 5). The activity of all of the MFS substrates increased
significantly in the presence of the compound against the wild-type
strains tested (8-fold for berberine, and 4-8-fold for EtBr and
fluroquinolones). The addition of 49,59-ODCQA in the more
susceptible E. faecalis NorA knock out mutant (Table 5) increased
the susceptibility of EtBr and norfloxacin (2–4 fold). This result
indicated the possible additional participation of the QacA MEP
system which has been implicated in the efflux of NorA substrates
[12,27]. Besides this anticipated complication, the ability of 49,59-
ODCQA to potentiate antibiotics was significantly weaker in the
case of the NorA knock out phenotypes, indicating a likely mode of
action associated with this MFS efflux system. Moreover the S.
aureus with NorA overexpression showed significant potentiation of
all antimicrobials and gave susceptibilities that were comparable
with the wild type counterpart in the absence of 49,59-ODCQA (8-
fold for berberine, between 4- 8-fold for EtBr and fluroquino-
lones). Results were similar when a B. cereus were used (data not
shown), implying a wider range of activity for 49,59-ODCQA.
49,59-ODCQA enhances accumulation of berberine in
Gram-positive bacteria
Berberine is a useful model plant antimicrobial whose
accumulation in microbial cells can be conveniently monitored
by measuring the fluorescence of berberine bound to DNA We
used three different Gram-positive bacteria, S. aureus, E. faecalis,
Figure 1. Hemolytic activity of caffeoylquinic acids towards
sheep erythrocytes. The CQA induced significantly more (*)
hemolysis, while DCQAs induced significantly virtually no hemolysis.
The data were analyzed by two-way repeated-measurement ANOVA for
the factors of different derivatives and derivative concentrations
followed by post hoc testing by the Holm-Sidak method (P,0.05).
Values are means6 SEM (n= 3). Note the log scales on both the x and y
axes.
doi:10.1371/journal.pone.0018127.g001
Table 2. Checkerboard assay for interaction of DCQAs with
BERB against S. aureus.
Compound FIC (compound) FIC (BERB) FICI
59-OCQA 0.50 0.50 1.00
39,59-ODCQA 1.00 1.00 1.00
49,59-ODCQA 0.125 0.0625 0.5
doi:10.1371/journal.pone.0018127.t002
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and B. cereus, to evaluate with a functional assay the EPI potential
of CQAs. We monitored an increase in berberine fluorescence,
assessing the rate of penetration and the level of accumulation of
berberine in S. aureus cells, in response to an established NorA
inhibitor (INF271) [28,29] and the selection of CQA derivatives
(Figure 2A) compared to berberine alone. Rapid accumulation
was also observed in other strains tested (E. faecalis, Figure 2B
and B. cereus data not shown). In all cases the potentiation of
uptake was maximal for 49,59-ODCQA. The effect was equal or
higher than that seen with INF271. Accumulation of berberine was
observed in the presence of 39,59-ODCQA and 59-OCQA,
although the rate and level of uptake were lower compared with
49,59-ODCQA, and closer to the baseline of berberine. This data
agrees with the EPI activity and the checkerboard assay data.
To study efflux, we loaded cells with berberine or the
combination of berberine with the compound at concentrations
significantly higher than those used for antimicrobial susceptibility
testing and then transferred them into fresh medium. Figure 3A
(S. aureus) and Figure 3B (E. faecalis) show that berberine efflux
was inhibited in the presence of 49,59-ODCQA both in wild type
strains as well as the S. aureus NorA overexpressing strain. The lack
of any effect in NorA knockout strains provides additional
evidence that 49,59-ODCQA is inhibiting NorA.
Biofilm inhibition with CQAs
In order to determine if members of the natural products of the
CQAs family were able to inhibit biofilm formation, alone and in
combination with a representative panel of antimicrobials, a
standard biofilm assay was conducted. The data are shown for S.
aureus in Figure 4A and for E. faecalis in Figure 4B. Only 59-
OCQA, when added alone, had a significant reduction in biofilm
viability in both strains whereas both DCQAs did not. Challenging
biofilms with CQA derivatives in combination with sub-inhibitory
concentrations of berberine, ethidium bromide, and the fluroqui-
nolone moxifloxacin gave a statistically significant decrease in
viability of biofilms in the presence of added 49,59-ODCQA. The
killing effect was increased 2 to 4 logs In the presence of 50 mg/ml
49,59-ODCQA, it was more pronounced in E. faecalis than S. aureus
for all antimicrobials tested. CQA enhanced the killing effect of the
compounds used in a less dramatic fashion when it was added in
both biofilm species at the same concentration. By contrast 39,59-
ODCQA had no apparent effect in either microorganism tested,
regardless of the antimicrobial employed. Quantitation of biofilm
formation and subsequent inhibition with or without treatments
was followed by reduction of OD600 after Crystal Violet staining
and Colony Forming Units (CFU) determinations. Results from
the CV stained biofilms were compatible with CFU determina-
tions but were omitted in the presentation for simplicity.
Molecular modeling studies
In order to gain structural insights into the interaction of the
potential EPIs (59-OCQA, 49,59-ODCQA and 39,59-ODCQA) with
two MES a. an ABC transporter [30] and b. a MFS
transporter[31] we used HADDOCK [32]. High quality models
could be obtained for all six protein-ligand complexes. Docking
results are consistent with our antimicrobial susceptibility tests and
the high-throughput competitive efflux assays performed in this
study: All CQAs can successfully enter the binding site of both
efflux pumps (Figure 5) remaining in the binding pockets
throughout the simulation runs. In addition, CQAs are predicted
to have different interaction energies with each efflux system:
Their preferential binding to the MFS transporter is governed by
hydrophobic interactions uniformly found in all solutions
(Table 6). Conversely, when interacting with the ABC transport-
er, electrostatic forces (ionic interactions and hydrogen bonds) are
dominant.
Table 3. Checkerboard assay of 49,59-ODCQA with
antimicrobials against MRSA.
Antibiotic (Dye) FIC (antibiotic or dye) FIC (49,59-ODCQA) FICI
CIPRO 0.20 0.00078 0.0039
NOR 0.10 0.00039 0.0039
LEVO 0.40 0.00156 0.0039
BERB 0.0312 0.0625 0.50
EtBr 0.0625 0.0156 0.0625
aEvaluated by the checkerboard method recommended by the CLSI and
expressed as the FIC index (FICI). A FICI of #0.5 indicates synergistic
interaction. FICI is calculated as the sum of the FICs of each agent. The FIC of
each agent is calculated as the MIC of the agent in combination divided by the
MIC of the agent alone.
CIPRO, ciprofloxacin NOR, norfloxacin LEVO, levoflaxin BERB, bebrerine,
EtBr, Ethidium Bromide.
doi:10.1371/journal.pone.0018127.t003
Table 4. Potentiation of antimicrobials by 49,59-ODCQA in S.
aureus.
S. aureus 8325-4
NorA 2/2 S. aureus
(MIC mg/mL)
NorA+/+ S.
aureus
alone
+49,59-
ODCQA alone
+49,59-
ODCQA alone
+49,59-
ODCQA
BERB 256 16 16 8 .512 64
EtBr 64 4 8 8 256 64
CIPRO 1 0.2 0.4 0.8 1 0.4
NOR 1 0.1 0.2 0.2 2 0.8
MOXI 1 0.2 0.4 0.4 1 0.4
LEVO 1 0.4 0.8 0.4 4 1
The strains S. aureus 8325-4 (wt) and the isogenic pair of knock out and
overexpression NorA mutant were used. All MIC determinations were
performed in triplicate. * 49,59-ODCQA was added at a final concentration of
10 mg/mL.
MOXI, moxifloxacin.
doi:10.1371/journal.pone.0018127.t004
Table 5. Potentiation of antimicrobials by 49,59-ODCQA in E.
faecalis.
OGRF1 (MIC mg/mL) norA2/2 E. Faecalis (MIC mg/mL)
alone +49,59-ODCQA alone +49,59-ODCQA
BERB 512 64 32 16
EtBr 128 8 16 4
CIPRO 2 0.8 1 1
NOR 1 0.2 0.4 0.2
MOXI 1 0.1 0.2 0.4
LEVO 1 0.1 0.2 0.1
The strains OGRF1(wt) and the knock out NorA mutant were used. All MIC
determinations were performed in triplicate. 49,59-ODCQA was added at a final
concentration of 10 mg/mL.
doi:10.1371/journal.pone.0018127.t005
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Interactions of the caffeoylquinic acids with the glycerol-
3-phosphate transporter (PDB ID: 1PW4)
59-OCQA exhibits strong binding to the glycerol-3-phosphate
transporter (see Table 6 and Figure 5, A). Besides the strong
desolvation energy component (-40.1610.2 kcal/mol), it is also
stabilized by increased electrostatics (2140.9618.3 kcal/mol).
For example, two Arg residues (R45 and R269) have been
observed to be crucial for the inhibition of the MFS transporter.
In our results, their side chains form salt bridges with the oxygen
atoms of the 59-O-caffeoylquinic acid (distance ,5.5 A˚)
(Figure 5A). K80, located at the transporter’s active site, forms
a salt bridge with the –COOH group of 59-OCQA. Results are
also very consistent as nearly all models fall into under one
cluster, with an average positional root mean square displace-
ment from the overall lowest-energy structure equal to
0.360.1 A˚.
For 39,59-ODCQA, the docking results in two low-energy
conformations (Table 6). Although their interaction energies are
quite similar and their location resembles that of the ‘classical
inhibitor’, striking differences in their hydrogen bond network are
observed (For details, see Figure S3). 49,59-ODCQA is found in the
binding site in an orientation similar to that of 39,59-ODCQA.
However, the significantly larger buried surface area (BSA) and
more favorable van der Waals energies are indicative of a tighter
fit into the binding site of the MFS efflux system than the other
inhibitors; in particular 39,59-ODCQA does not show such an
extent in complementarity.
Interactions of caffeoylquinic acids with the Sav1688 ABC
transporter (PDB ID: 2HYD)
The ABC transporter was modeled in its open conformation
(Figure 5B) (Figure S4 and Table S1), using as template the
crystal structure of its close sequential and structural homologue,
the P-glycoprotein in its open form (PDB ID: 3G61) [33]. All
caffeoylquinic acids successfully entered the active site of the ABC
transporter (Figure 5B). Besides the favorable Electrostatics
(Figure 5B), the desolvation penalty is quite large (Table 6).
Results are rather similar to the ones shown above for the MFS
transporters with one major cluster with over 140 members. All
other clusters were small in size (,10 structures were included).
Binding of this molecule to the ABC transporter is, however, not as
energetically favored as to the MFS transporters (for comparison
of the interactions, see Table 6 and Figure 5A and 5B). For the
other two EPIs, more clusters were obtained. As was already the
case with the docking to the MSF transporters, in all solutions,
49,59-ODCQA occupies a much larger area in the binding site
compared to 39,59-ODCQA; van der Waals interactions of these
EPIs also follow the same principle (Table 6).
All the above mentioned results can rationalize the strong
observed binding of 49,59-ODCQA and 59-OCQA and the lower
Figure 2. Berberine accumulation with caffeoylquinic acids in Gram-positive bacteria. The uptake of berberine with no addition or with
the addition of 59-OCQA, 39,59-ODCQA, 49,59-ODCQA, or INF271 by cells of S. aureus (A), E. faecalis (B), was measured by determination of the increase
in fluorescence following binding to DNA and is expressed as relative fluorescence units (RFU). Berberine was present at a concentration of 30 mg/ml,
and 59-OCQA, 39,59-ODCQA, 49,59-ODCQA, INF271 were added at the same final concentrations used for the MIC determinations.
doi:10.1371/journal.pone.0018127.g002
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efflux pump inhibition of 39,59-ODCQA. They suggest that, for
the MFS efflux systems, all molecules could potentially inhibit the
active site; however, 59-OCQA exhibits in both cases a
substantially smaller interaction region showing less complemen-
tarity. The docking of all CQAs in the binding sites of the ABC
transporter, reveals an abundance of charged interactions. 39,59-
ODCQA shows a decreased complementarity within the active site
compared to that of 49,59-ODCQA. Observed interactions with
residues within the active sites are similar to the ones described in
the literature for other EPIs [34,35].
We, therefore, formulate a hypothesis consistent with the
derived energetics, that CQAs show a preferential binding to
MFS efflux systems, rather than to ABC transporters. The
reported energies provide insights into the interaction of the EPIs
with efflux systems and contribute to a working hypothesis
regarding the molecular mechanisms behind their observed
inhibitory activities. They should, however, be interpreted with
caution and only in terms of estimates of potential of binding
and not as binding affinities [36]. Studies including Surface
Plasmon Resonance or Isothermal Titration Calorimetry to
determine Kd’s or DG’s will offer further insights in this primary
hypothesis.
Synopsis
An array of natural product screening and synthesis campaigns
led to the identification of a variety EPI chemotypes targeting
NorA. The list includes catechin gallates [37], the resin glycosides
and tetrasaccharide agents of Ipomoea murucoides [38], polyacylated
oligosaccharides from the medicinal Mexican morning glory
species [39], N-caffeoylphenalkylamide derivatives [40], citral
derived amides [41] kaempferol glycoside from Herissantia tiubae
(Malvaceae) [42] and a set of plant-based alkaloids against
methicillin-resistant S. aureus (MRSA) [43]. A series of plant
phenolic compounds have been functioning as ethidium bromide
EPIs in Mycobacterium smegmatis [44]. A series of synthetic efforts
have been concentrated in paroxetine and femoxetine [45],
piperine and fluoroquinolone as the basis for designing structural
analogues [46,47], phenothiazines [48] with emphasis on
thioridazine and chlorpromazine [49]. All these explorations are
focusing in the bioassay driven purification and structural
determination of natural EPIs employing an EtBr effux assay. In
retrospective this venture offers a rapid methodological alternative
to the direct isolation of active compounds as well as attempts to
enrich the EPI discovery process with an extensive and
rationalized secondary validation of lead chemotypes. The
Figure 3. Efflux potentiation by 49,59-O-dicaffeoylquinic acid in S. aureus (A), E. faecalis (B). Efflux was measured using berberine by
determination of the decrease in fluorescence following binding to DNA and is expressed as % fluorescence. Cells were loaded with berberine at a
concentration of 100 mg/ml, and then resuspended in buffer in the absence or presence of 49,59-ODCQA, at the same final concentrations used for
the MIC determinations.
doi:10.1371/journal.pone.0018127.g003
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antimicrobial and toxicity profile of caffeoylquinic acids combined
with prior art and information regarding their impact in anti-
oxidant defenses in mammalian systems suggests a potential
similar role in bacteria. The direct antimicrobial activity of CQA
implies an array of possibilities including effect in the cell envelope
and requires a robust target based validation and investigation.
Materials and Methods
Microbial strains and culture conditions
The following bacterial strains were used in this study: S. aureus
8325-4 (wild-type); K1758 (8325-4 DnorA); QT1 8325-4 norR::cat
(NorA is overexpressed [50], S. aureus Community Associated
Figure 4. Potentiation of biofilm inactivation by CQAs in combination with model antimicrobials. (A) Biofilms of S. aureus 8325-4 were
significantly more sensitive to berberine, ethidium bromide and representative fluroquinolones in the presence of the EPI 49,59-ODCQA.
Antimicrobials in sub-lethal/inhibitory concentrations (100 mg/ml for berberine, 10 mg/ml for EtBr and 2 mg/ml for moxifloxacin respectively) were
added to 48 hr biofilms that had been grown in media with and without CQAs. After 2 h of exposure to antimicrobials the biofilm density was
assessed by determining the number of CFUs per microtiter well (i) and the absorbance of crystal violet (CV)-stained biofilms at 600 nm (ii). In the
presence of CQAs (50 mg/ml), (B) Biofilms of E. faecalis OGRF1 strain showed large increases in EtBr susceptibility in the presence of 4959-ODCQA.
48 hr biofilms were exposed to sub-inhibitory concentrations of antimicrobials (50 mg/ml for berberine, 8 mg/ml for EtBr and 1 mg/ml for moxifloxacin
respectively) for 2 h after growth in media with and without CQAs. The size of the viable biofilm was found by calculating the number of CFUs per
microtiter well (i) and the absorbance of crystal violet (CV)-stained biofilms at 600 nm (ii).for three independent experiments and statistical
significance determined by a paired two-tailed t test).
doi:10.1371/journal.pone.0018127.g004
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(CA)-MRSA USA300 (Human isolate/Clinical Microbiology,
MGH), E. faecalis OGRF1 (Fusr Rifr; p-Cl-Pher), E. faecalis
GW4481 (OG1RFDemeA, [51], Escherichia coli K12 (ATCC),
prototrophic wild type reference strain Candida albicans DAY185
[52]. Bacterial cells were cultured in Mueller–Hinton Broth
(MHB) and yeast cells in YPD (unless is otherwise stated). Cell
growth was assessed with a spectrophotometer (Shimadzu, Mini
1240) at 600 nm (OD600).
Chemicals
All solvents used in chromatography were of HPLC grade from
Lab-Scan Analytical Sciences Ltd. (Dublin Ireland); Formic acid
from Merck (Haarlem, The Netherlands) and H2O was produced
in-house (Milli-Q Water Purification System, Millipore). Acetoni-
trile-d3 (99.8%) was obtained from Cambridge Isotope Laborato-
ries (Apeldoorn, The Netherlands). Antibiotics (erythromycin,
tetracycline) and antimicrobials (berberine, ethidium bromide,
rhodamine 6G, chlorogenic acid) were purchased from Sigma
Chemical Co. (St. Louis, Mo.). Fluroquinolones (norfloxacin,
ciprofloxacin, levofloxacin and moxifloxacin) were from the Massa-
chusetts General Hospital Pharmacy (http://www.massgeneral.
org/services/pharmacy.aspx) INF271 was provided by Chembridge
Inc. San Diego, CA) 19,39 & 19,59-ODCQA as well as peracetylder-
ivatives of both DCQAs, were kindly provided by Jiri Slanina
(Department of Biochemistry Faculty of Medicine Masaryk Univer-
sity in Brno [53] and 39,59-ODCQA, 49,59-ODCQA by Cfm Oskar
Tropitzsch e.K. (Marktredwitz, Germany).
Plant Material & Aqueous infusions
Artemisia absinthium, growing wild in Epirus region (Northwestern
Greece) was collected in the period from spring to summer. 2 g of
dried aerial parts of A. absinthium, ground to pass a 0.4 mm sieve,
were added to 50 ml of boiling double distilled water (DDW) and
stirred for 30 min. The plant residue was then filtered, and the
Figure 5. Docking results and interactions within the binding pockets of MES for of all CQAs. All CQAs can successfully enter the binding
sites of both efflux systems (A, B). See also Table 3 for the calculated energetics.
doi:10.1371/journal.pone.0018127.g005
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filtrate was lyophilized. The 40 mg of dried extract produced were
analyzed for the determination of its main active components.
Plant materials and aqueous infusions preparations as well as
instrumentation used for the analysis of the constituents are
reported in Text S1.
Susceptibility testing
Cells (105/ml) were inoculated into MHB (RPMI for C. albicans)
and dispensed at 0.2 ml/well in 96-well microtiter plates. Growth
inhibition was determined by serial 2-fold dilution of test extract or
compounds in 96-well microtiter plates to determine Minimal
Inhibitory Concentrations (MICs). In order to identify compounds
with EPI activity, extracts and compounds were serially 2-fold
diluted in combination with 30 mg/ml berberine for gram-positive
bacteria, 10 mg/ml erythromycin for E. coli, and 10 mg/ml
rhodamine 6G (R6G) for yeast cells. An EPI was defined as a
compound that completely prevented cell growth in the presence
of sub-inhibitory antibiotic during an 18-hr incubation at 37uC or
24–48 hr at 30uC (B. cereus, C. albicans). All tests were done in
triplicate by following the Clinical and Laboratory Standards
Institute (CLSI, former NCCLS, National Center for Clinical
Laboratory Standards) recommendations [54,55]. Growth was
assayed with a microtiter plate reader (Spectramax PLUS384,
Molecular Devices) by absorption at 600 nm. The checkerboard
tests for DCQAs and antimicrobials were performed as previously
described [56]. For each combination experiment (composed of a
row or column in the matrix), the Fractional Inhibitory
Concentration (FIC) of each agent was calculated: FIC = 1
additive effect; FIC,1, synergy; FIC.1 antagonism.
Hemolysis assay
The ability of CQAs to hemolyze sheep erythrocytes is based on
the protocol of Ciornei et al. [57], with the following modifications
[58]: sheep erythrocytes (Rockland Immunochemicals) were
treated with CQAs (0.5–50 mg/ml) in PBS with DMSO at 2%
and the supernatants for 2 h, using Triton X-100 and DMSO as
controls, and were monitored on a microtiter plate reader
(Spectramax PLUS384, Molecular Devices) at OD540.
Berberine accumulation assays
Determination of berberine uptake was performed as described
previously [9,59]. Cells were cultured with aeration at 37uC to an
optical density at 600 nm (OD600) of 1.8, pelleted, and washed
twice with 20 mM HEPES-NaOH (pH 7.0) buffer. The cells were
then resuspended to an OD600 of 0.3 in 1 ml of HEPES buffer
containing 10 mM glucose followed by incubation at 37 or 30uC
for 1 h. The cells were centrifuged, washed, and resuspended at an
OD600 of 0.15 in HEPES buffer. Assays were performed in 96-well
flat-bottom black plates (Costar) in a final volume of 200 ml.
Berberine was added at 30 mg/ml, and fluorescence was measured
with a Spectramax Geminis spectrofluorometer (Molecular
Devices) at a 355-nm excitation wavelength and a 517-nm
emission wavelength.
Berberine competitive efflux assay
Those were performed as described [59]. S. aureus and E. faecalis
cells were cultured with aeration and mild agitation until they
reached the late log phase (OD600 between 0.9 and 1), pelleted by
centrifugation (2 min, 12,000 rpm), and then washed and
resuspended in 25 mM PBS (pH 7.4) containing 0.05 g L21
MgSO4, 7 g L
21 K2HPO4, 0.5 g L
21 sodium citrate?3H2O, 1 g
L21 (NH4)2SO4, 0.01 mg L
21 folic acid, 0.05 mg L21 pyridoxine
hydrochloride, 0.025 mg L21 riboflavin, 0.01 mg L21 biotin,
0.025 mg L21 thiamine, 0.025 mg L21 nicotinic acid, 0.025 mg
l21 calcium pantothenate, 0.5 mg L21 vitamin B12, 0.025 mg L21
p-aminobenzoic acid, 0.025 mg L21 thiotic acid, and 4.5 mg L21
monopotassium phosphate. Cells were then resuspended to an
OD600 of 0.8 in buffer with 10 mM glucose. Cells were then
loaded with either 30 mg/ml berberine and 10 mg/ml 49,59-
ODCQA and incubated at 37uC with aeration for 20 min. Cells
were then centrifuged in a 4uC cold room, washed in ice-cold PBS,
and added at an OD600 of 0.3 to a chilled 96-well flat-bottom
white microtiter plate (Costar) containing ice-cold 25 mM PBS
and 10 mM glucose in a final volume of 200 mL. Fluorescence was
measured with a Spectramax PLUS384 GeminiXS spectrofluo-
rometer (Molecular Devices) at a 355-nm excitation wavelength
and a 517-nm emission wavelength.
Table 6. Energetic contributions and cluster sizes for each docking run.
Efflux Pump
PDB IDa
Cluster
sizeb RMSdd (A˚)
Haddock Score
(kcal/mol)
Van der Waals
(kcal/mol)
Electrostatics (kcal/
mol)
Desolvation
(kcal/mol) BSA (A˚2)
59-OCQA 1PW4 198 0.360.2 290.367.2 222.060.7 2140.9618.3 240.1610.2 671638
2HYD* 146 0.360.2 21.364.6 29.763.4 2161.5624.2 40.669.3 498683
39,59-ODCQA 1PW4 116 0.360.2 2108.263.6 227.762.8 2151.5610.1 250.263.5 825632
82 0.560.0 298.164.4 227.161.8 2146.7620.7 241.767.1 823664
2HYD* 7 0.360.2 0.168.0 222.963.5 2182.0618.6 58.562.5 716657
94c 0.560.0 2.867.1 217.965.7 2176.8625.0 55.965.4 623672
49,59-ODCQA 1PW4 88 0.360.2 2108.1611.0 238.263.0 2137.1612.2 242.4611.5 931648
109 0.560.1 2103.962.9 232.863.4 2169.7632.1 237.266.3 952622
2HYD* 82 0.360.2 28.763.9 220.861.5 2185.7632.5 49.165.7 766670
See text for details and materials and methods for column header definitions.
a1PW4 corresponds to the PDB ID glycerol-3-phosphate transporter from Escherichia coli and 2HYD* to the modeled open conformation of Sav1688 ABC transporter.
bSize of top ranking clusters. Clustering was performed with a 7.5 A˚ cutoff based on pairwise interface ligand RMSDs, the RMSD of the ligand after fitting on the binding
site of the receptor.
cThis cluster scored second on the top; the first cluster included only 7 structures and the energetics were very similar (see Table).
dRMSd is the average Root mean square displacement from the top four ranking model of a cluster from its top ranking member, calculated on the backbone atoms of
the protein and all heavy atoms of the ligand.
doi:10.1371/journal.pone.0018127.t006
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Biofilm formation & Quantitation
Biofilm formation is assayed by the ability of cells to adhere on
polystyrene surface of 24-well microtiter plates [60]. The indicated
medium is inoculated from a 1:100 dilution from an overnight
BHI culture. Plates are incubated at 37uC for 48 hrs. Compounds
are added at the appropriate combinations and concentrations
followed by additional overnight incubation at 37uC. Two
identical microtiter plates were used for each independent
experiment. For the first plate crystal violet (CV) solution was
added to each well, the plates were incubated at room
temperature, rinsed thoroughly with water and dissolved. CV-
stained biofilms were solubilized in ethanol, and samples were
transferred to a new polystyrene microtiter dish, and the
absorbance was determined with a plate reader at 600 nm. For
the second plate cells are dissolved followed by CFU determina-
tions on BHI agar plates.
Statistics
For the toxicity experiments studies values are means of three
separate experiments and bars are SEM. For biofilm inactivation
studies, between means were tested for significance by a paired
two-tailed t test The significance level was set at p,0.05.
Structure-activity relationships and comparative protein-
ligand docking studies
Two efflux pump crystal structures [34,35] were selected to
perform comparative docking of caffeoylquinic acids to their
binding sites: the glycerol-3-phosphate transporter from Escherichia
coli [35] (PDB ID: 1PW4) was the representative structure from the
MFS, and Sav1866 from Staphylococcus aureus [34,35] (PDB ID:
2HYD), is an ABC transporter of Gram-positive bacteria. 2HYD
was crystallized in the closed conformation. Since 2HYD shares
very high structural similarity with P-glycoprotein [34,61], the
open conformation was generated by flexible structural alignment
with FATCAT (http://fatcat.burnham.org/) against the corre-
sponding P-glycoprotein crystal structure [61] (PDB ID: 3G61).
This approach concluded in a good quality model (see Figure S3
and Table S1).
For the docking trials, HADDOCK version 2.1 [62] was used.
HADDOCK is a highly successful modeling approach that makes
use of biochemical and/or biophysical interaction data such as
chemical shift perturbation data, mutagenesis data, or bioinfor-
matic predictions and thus, incorporates structural knowledge of
the target to drive the docking procedure. The docking was
performed with default parameters using the web server version of
HADDOCK [63]. All calculations were performed with CNS1.2
[64]. Non-bonded interactions were calculated with the OPLS
force field [65] using a cutoff of 8.5 A˚. The electrostatic potential
(Eelec) was calculated by using a shift function, while a switching
function (between 6.5 and 8.5 A˚) was used to define the Van der
Waals potential (Evdw). The HADDOCK score is used to rank the
generated poses. It is a weighted sum of intermolecular
electrostatic (EElec), van der Waals (EvdW), desolvation (DGsolv)
and ambiguous interaction restraint (AIR) energies with weight
factors of 0.2, 1.0, 1.0 and 0.1, respectively.
The ambiguous interaction restraints to drive the docking were
defined as follows. The ligand was treated as an active residue for
all stages of the docking, while the residues within the protein
binding site were only defined as active for the rigid-body docking
stage and considered as passive the subsequent semi-flexible
refinement stage. This strategy allows to effectively pulling the
ligand within the binding site during rigid-body docking while
allowing a more thorough exploration of the binding pocket
during the refinement stage. Residues considered active for 1PW4
were 38, 42, 45, 46, 134, 165, 166, 266, 269, 270, 299, 362 and
393, whereas for 2HYD*, the active residues were 26, 252, 255,
288, 291, 295, 604, 608, 611, 612, 614, 648, 722, 837, 866, 869,
870, 873, 874 and 896. Passive residues were defined automat-
ically via the web-server, as those surrounding the active ones.
Supporting Information
Figure S1 400 MHz 1H-NMR spectrum of 1, in CD3CN.
The spin system corresponding to 59-OCQA is revealed. The H-2/
and H-6/signals of the quinic moiety are overlapped by the
CD3CN-H2O residual signals and, therefore, they are eliminated.
(TIFF)
Figure S2 400 MHz 1H-NMR spectrum of 2A and 2B, in
CD3CN. The spin system of 39,59-ODCQA (2A) is mainly
indicated while that one of 49,59-ODCQA (2B) is suggested in
italics. The signals of the aromatic protons of 2B are greatly
overlapped by those of the 2A isomer and, thus, are not indicated
in the spectrum.
(TIFF)
Figure S3 View of protein-ligand hydrogen bonds in the
top two clusters of the modelled complex of 39,59-
ODCQA with 1PW4: (A) top ranking cluster, (B) second,
most populated cluster. The different orientations of the 39,59-
ODCQA is reflected in the differences in the hydrogen bonding
pattern. For example, 39,59-ODCQA, show a different pattern of
hydrogen bonds of the carbonyl groups, interacting in one case
with the side chains of Y38, Y42 and W261 whereas in the second
cluster the observed hydrogen bonds are different and fewer in
number This figure was generated with PyMol (www.pymol.org).
(TIFF)
Figure S4 Ramachandran plot of the model of Sav1688
in the open conformation. The plot is based on an analysis of
118 structures of resolution of at least 2.0 A˚ and an R-factor no
greater than 20%. A good quality model would be expected to
have over 90% in the most favoured regions. Plot statistics:
Residues in most favoured regions [A,B,L], 1001 (95.5%).
Residues in additional allowed regions, [A,B,L,P], 43 (4.1%).
Residues in generously allowed regions, [,A, ,B, ,L, ,P], 2
(0.2%). Residues in disallowed regions, 2 (0.2%). Number of non-
glycine and non-proline residues, 1048 (in total: 100.0%). Number
of end-residues (excl. Gly and Pro), 4. Number of glycine residues
(shown as triangles), 74. Number of proline residues, 30. Total
number of residues: 1156.
(TIFF)
Table S1 PSVS (http://psvs-1_4-dev.nesg.org/) valida-
tion statistics of the modelled open form (2HYD*) and,
for comparison, of the crystal structure 2HYD.
(TIFF)
Text S1 Plant materials and aqueous infusions prepa-
rations as well as instrumentation used for the analysis
of the constituents of Artemisia absinthium extracts.
(DOC)
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